IFNA2 and melanoma: Li et al. [35] in the Hangzhou (CN) center also reported no significant difference in RFS (not reached vs. 25 mo) for stage III melanoma between the pembrolizumab and IFN-α-2b groups (HR = 1.20, p = 0.75).